Financials data is unavailable for this security.
View more
Year on year PURE Biosciences Inc 's net income fell 13.46% from a loss of 3.49m to a larger loss of 3.96m despite flat revenues. A contributing factor has been an increase in the selling, general and administrative costs as a percentage of sales from 213.71% to 222.96%.
Gross margin | 57.29% |
---|---|
Net profit margin | -173.41% |
Operating margin | -168.15% |
Return on assets | -264.29% |
---|---|
Return on equity | -- |
Return on investment | -480.58% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at PURE Biosciences Inc fell by 2.30m. Cash Flow from Financing totalled 1.02m or 54.08% of revenues. In addition the company used 3.28m for operations while cash used for investing totalled 33.00k.
Cash flow per share | -0.0313 |
---|---|
Price/Cash flow per share | -- |
Book value per share | -0.0192 |
---|---|
Tangible book value per share | -0.0192 |
More ▼
Balance sheet in USDView more
Current ratio | 1.30 |
---|---|
Quick ratio | 1.19 |
Total debt/total equity | -- |
---|---|
Total debt/total capital | 9.45 |
More ▼